Clinical Trial: A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07499700) titled 'A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis' on March 24.

Brief Summary: This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis

Study Start Date: Oct. 26, 2025

Study Type: INTERVENTIONAL

Condition: Minimal Change Disease (MCD) Focal Segmental Glomerulosclerosis (FSGS)

Intervention: DRUG: BAT4406F

100 mg/5 mL Dosage and Administration: Intravenous infusion; 500 mg per dose. Dosage Schedule: P...